Verastem Past Earnings Performance

Past criteria checks 0/6

Verastem has been growing earnings at an average annual rate of 7.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 47.7% per year.

Key information

7.6%

Earnings growth rate

40.9%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-47.7%
Return on equity-290.1%
Net Margin-934.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Verastem makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:2VSA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2410-934183
30 Jun 2410-893772
31 Mar 240-1063467
31 Dec 230-873161
30 Sep 230-772850
30 Jun 230-752747
31 Mar 230-732649
31 Dec 223-742551
30 Sep 223-732551
30 Jun 223-782449
31 Mar 224-732444
31 Dec 212-712439
30 Sep 212-752638
30 Jun 2181-393840
31 Mar 2184-454739
31 Dec 2089-685941
30 Sep 2092-877543
30 Jun 2022-1308045
31 Mar 2021-1499346
31 Dec 1917-14910146
30 Sep 1915-12210442
30 Jun 1922-11310741
31 Mar 1928-899342
31 Dec 1827-727744
30 Sep 1826-795846
30 Jun 1810-813852
31 Mar 180-762649
31 Dec 170-682146
30 Sep 170-611942
30 Jun 170-461829
31 Mar 170-411824
31 Dec 160-361720
30 Sep 160-371721
30 Jun 160-441728
31 Mar 160-511734
31 Dec 150-581841
30 Sep 150-601843
30 Jun 150-581840
31 Mar 150-551838
31 Dec 140-531835
30 Sep 140-511734
30 Jun 140-481731
31 Mar 140-451629

Quality Earnings: 2VSA is currently unprofitable.

Growing Profit Margin: 2VSA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2VSA is unprofitable, but has reduced losses over the past 5 years at a rate of 7.6% per year.

Accelerating Growth: Unable to compare 2VSA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2VSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 2VSA has a negative Return on Equity (-290.06%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:29
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Verastem, Inc. is covered by 27 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Matthew CrossAlliance Global Partners
Kalpit PatelB. Riley Securities, Inc.